Decker N, Grima M, Velly J, Marciniak G, Leclerc G, Schwartz J
Institut de Pharmacologie, Faculté de Médecine, Strasbourg, France.
Arzneimittelforschung. 1987 Oct;37(10):1108-12.
A series of 3-, 4-, 5-, 6-, 7- and 8-pyridyl-2(1H)-quinolones and related compounds were evaluated for positive inotropic and vasodilatory activities in vitro. Most of them produced dose-related increases in myocardial contractility on guinea pig isolated atria and perfused heart. In guinea pig atria, the 6-pyridyl molecules were more active than the 5-pyridyl ones; the mean ED50 of compounds 14, 32 and 33 was 4.0 x 10(-7) mol/l i.e. 33 times that of sulmazole; that of compounds 6 and 7 was 2.0 x 10(-5) mol/l. The potencies of the 5- and the 6-pyridyl series also differed by 2 log units on perfused guinea pig heart. The 5- and 6-pyridyl series induced relaxation in precontracted pig coronary artery and coronary vasodilation on perfused guinea pig heart. Compounds 14, 32 and 33 also showed alpha-adrenolytic properties, which were by 0.7 log unit lower than that of phentolamine. These results indicate that this novel cardiotonic series exert positive inotropic and coronary vasodilatory effects.
对一系列3-、4-、5-、6-、7-和8-吡啶基-2(1H)-喹诺酮类化合物及相关化合物进行了体外正性肌力和血管舒张活性评估。它们中的大多数对豚鼠离体心房和灌注心脏的心肌收缩力产生剂量相关的增加。在豚鼠心房中,6-吡啶基分子比5-吡啶基分子更具活性;化合物14、32和33的平均ED50为4.0×10(-7)mol/L,即舒马唑的33倍;化合物6和7的平均ED50为2.0×10(-5)mol/L。在灌注豚鼠心脏上,5-和6-吡啶基系列的效力也相差2个对数单位。5-和6-吡啶基系列可使预收缩的猪冠状动脉舒张,并使灌注豚鼠心脏的冠状动脉扩张。化合物14、32和33还表现出α-肾上腺素能阻断特性,其活性比酚妥拉明低0.7个对数单位。这些结果表明,这个新型强心剂系列具有正性肌力和冠状动脉舒张作用。